632 Russell St.
22 articles with Bexion Pharmaceuticals
Bexion Pharmaceuticals, Inc. announced today that it has added RJ. Tesi, M.D. to its Board of Directors. Dr. Tesi has a distinguished career as a biotech entrepreneur and an experienced surgeon. C
Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have been accepted for oral or poster presentation: Oral Pre
Bexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG). DIPG primarily affects children, with most diagnoses occurring between 5 and 7 years of age
In the Type B meeting, the FDA provided guidance on various design aspects of Bexion's proposed Phase 2 clinical trial.
Bexion Pharmaceuticals, Inc. announced that the company has added Bob Savage, MBA to its Board of Directors.
Bexion Pharmaceuticals, Inc. announced that the Board of Directors and shareholders approved the increase of the Series B Preferred Stock Financing to $25MM. $16.6MM has been collected to date.
Bexion Pharmaceuticals Experiences Robust Enrollment of Phase I Part 3 First-In-Human Trial Using BXQ-350 for the Treatment of Cancer
The purpose of Part 3 is to explore safety, and additional indications in rare and gastrointestinal tumors.
Bexion Pharmaceuticals Announces the Opening of Phase I Part 3 First-in-Human Trial Using BXQ-350 for the Treatment of Cancer
Bexion Pharmaceuticals, Inc. announced the opening of Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer.
The biotech industry is fast-moving and dynamic, and staying on top of all the news can be hard for our busy readers. Here’s a look back at some of the top stories you may have missed this month.
Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John Mc...
8/27/2018McCain died Saturday after deciding to discontinue treatment for brain cancer. He approached the end of his life in the same manner in which he approached me that day in Raleigh – with the strength of character.
Bexion Pharmaceuticals is not a household name as far as drugmakers go. But, this week the company and its investigational cancer treatment, BXQ-350, is receiving lots of mainstream media coverage as a potential game-changer.
Cytovance Biologics Announces Bexion Pharmaceuticals Has Chosen Cytovance to Manufacture the Protein Component and Active Ingredient Of Bexion’s First Clinical Compound, BXQ-350
An ongoing supply of this protein will support Bexion’s continued drug development efforts, including planned Phase II clinical trials.
Bexion Pharma Announces Initiation of Phase 1b Clinical Trial of BXQ-350 in Patients with Advanced Solid Tumors in Collaboration with CTI Clinical Trial and Consulting
The company announced in September 2017 the successful completion of the First-in-Human Phase 1a trial, where four sites.
Bexion Pharmaceuticals And CTI - Clinical Trial and Consulting Services Announce Completion Of First-In-Human Trial Using BXQ-350 For The Treatment Of Cancer
Bexion Pharmaceuticals Doses First Patient In Phase I Trial Of BXQ-350 For Patients With Advanced Solid Tumors At The University Of Cincinnati Cancer Institute
Bexion Pharmaceuticals Receives FDA Clearance For The First Clinical Trial Using BXQ-350 To Dose Patients With Cancer
Bexion Pharmaceuticals Receives Orphan Drug Designation For Saposin C, The Active Ingredient In BXQ-350 For Glioblastoma Multiforme From FDA
Bexion Pharmaceuticals Awarded $2.9MM SBIR Bridge Award by National Cancer Institute to Support Phase I First-in-Human Clinical Trial in Cancer